Quarterly ResultMay 13, 2026, 04:18 PM
Dyadic Q1 Revenue Jumps 182.3% to $1.11M; Net Loss Narrows
AI Summary
Dyadic International reported a significant increase in total revenue for Q1 2026, rising 182.3% to $1.11 million, while its net loss narrowed to $1.95 million. The company highlighted several key commercial advancements, including the launch of AlbuFree DX recombinant human albumin, an expanded collaboration with Fermbox Bio for recombinant DNase I, and new distribution and development agreements. Dyadic continues to focus on commercializing animal-free recombinant proteins and enzymes through strategic partnerships and direct sales channels.
Key Highlights
- Q1 2026 total revenue increased 182.3% to $1,110,956.
- Q1 2026 net loss narrowed to $1,954,683, or $(0.05) per share.
- Cash, cash equivalents, restricted cash, and investment grade securities totaled $6.6 million.
- Commercial launch of AlbuFree DX recombinant human albumin by Proliant Health & Biologicals.
- Expanded collaboration with Fermbox Bio, launching recombinant DNase I.
- Signed OEM distribution agreement with IBT Bioservices for recombinant products.
- Entered development and commercialization agreement with BRIG Bio for alpha-lactalbumin.
- R&D expenses decreased 3.8% to $476,069.
Price Impact
More from DYAI